From Yahoo Finance: 2025-06-11 19:54:00

BridgeBio Pharma, Inc. had its price target raised to $56 from $53 by H.C. Wainwright. The company is among the 13 Biotech Stocks with Huge Upside Potential according to Raghuram Selvaraju. The positive momentum is driven by the fast uptake of the Attruby product for adult patients with ATTR-CM, which is nearly full stabilizer of Transthyretin (TTR) approved in the U.S. to lower cardiovascular mortality and hospitalizations. Side effects included abdominal pain and diarrhea, but BridgeBio Pharma provides initiatives for patient access to medications. The company is a novel biopharmaceutical business focused on developing revolutionary medications for hereditary disorders. While BBIO has potential as an investment, certain AI stocks may offer greater upside potential. For more information on AI stocks, refer to the article on the best short-term AI stock. No disclosures were made in the article.



Read more at Yahoo Finance: BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright